IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

Targeted Drug Delivery in Cancer Therapy

Pranita Sanjay Dudhe[1] and Rutuja Thakare[2]
Guide, Assistant Professor, Vardhaman College of Pharmacy, Karanja (Lad), Maharashtra, India[1]
Student, Vardhaman College of Pharmacy, Karanja (Lad), Maharashtra, India[2]

Abstract: *Targeted medication delivery in cancer therapy is a promising method for increasing efficacy while minimizing side effects. This technique uses NANO materials, antibodies, or LIGAND-conjugated medicines to deliver medications directly to cancer cells while limiting damage to healthy organs. Advances in nanotechnology, such as liposomes, DENDRIMERS, and NANO particles, have enabled precise tumor targeting based on specific molecular markers expressed on cancer cells. Furthermore, the emergence of stimuli-responsive drug delivery systems, which release their payload in reaction to environmental changes like pH, temperature, or certain enzymes, provides new opportunities for site-specific treatment. Clinical trials have shown improved therapeutic outcomes, such as increased medication stability, decreased systemic toxicity, and improved tumor targeting. However, issues like immune system evasion, scalability, and tumor heterogeneity remain to be solved. Further research and innovation in tailored drug delivery platforms show significant promise for transforming cancer treatment, enhancing patient quality of life, and potentially overcoming resistance to standard medicines[1].*

Keywords: Anticancer drugs, Tumor cells, Bio conjugates, Particles, vascular

I. INTRODUCTION

Targeted medication delivery in cancer therapy is a promising method for increasing efficacy while minimizing side effects. This technique uses NANO materials, antibodies, or LIGAND-conjugated medicines to deliver medications directly to cancer cells while limiting damage to healthy organs. Advances in nanotechnology, such as liposomes, DENDRIMERS, and NANOparticles, have enabled precise tumor targeting based on specific molecular markers expressed on cancer cells. Furthermore, the emergence of stimuli-responsive drug delivery systems, which release their payload in reaction to environmental changes like pH, temperature, or certain enzymes, provides new opportunities for site-specific treatment.

Clinical trials have shown improved therapeutic outcomes, such as increased medication stability, decreased systemic toxicity, and improved tumor targeting.However, issues like immune system evasion, scalability, and tumor heterogeneity remain to be solved. Further research and innovation in tailored drug delivery platforms show significant promise for transforming cancer treatment, enhancing patient quality of life, and potentially overcoming resistance to standard medicines[1]

1) In most parts of the world, cancer remains one of the leading causes of death. (2) Routine screening has improved our understanding of the process of tumor progression and early sickness prognosis, resulting in a multitude of new therapy options.After the majority of solid tumors are surgically removed, the cancer cells that remain are treated with a variety of treatments, including immunotherapy, chemotherapy, and radiation.

(3) Chemotherapy is the chosen treatment if the cancer has spread because there are few other options. The fundamental cause of chemotherapy failure is the chemotherapeutic non selective nature of antineoplastic medications, which leads to severe toxicity, and their low accessibility to the tumor, necessitating higher doses.

(4) Accordingly, by selectively distributing Targeted drug delivery, which selectively delivers therapeutically effective medicine concentrations to the tumor area, offers huge promise to improve cancer treatment.The purpose of this study is to provide a general overview of the concerns surrounding targeted medication delivery in cancer, as well as to shed light on the challenges associated with developing cancer-specific targeted delivery systems.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

Need for targeted drug delivery

All treatment strategies assume the quest of therapeutic agent specificity. The specificity of a drug's action is critical in cancer treatment, as chemotherapeutic and radiotherapeutic techniques seek to eliminate cells. The basic idea underlying these strategies is to destroy cancer cells selectively while causing minimal harm to healthy cells.

To achieve complete remission in individuals with a disseminated disease, all cancer cells must be killed, either directly by the drug's action or indirectly through the therapy's bystander impact. Chemotherapy regimens alone are not always helpful in treating aggressive carcinomas and often result in only transitory improvements. Combination therapy, which combines high radiation doses (60-70 GY) with continuous infusion of chemotherapy medicines, such as PACLITAXEL, has been investigated for the treatment of incurable locally advanced malignancies.[2] Because PACLITAXEL radio sensitizes tumor cells, combined therapy is more effective than either drug or radiation therapy alone.

Maintaining therapeutically meaningful drug concentrations in solid tumors is crucial for effective treatment. Even after long-term administration of these toxic treatments, residual tumor cells remain due to the medications' inability to penetrate the physiologically varied tumor bulk. High dose therapy required to sustain complete remission generates unpleasant systemic adverse effects, prompting many patients to discontinue treatment. The bulk of these side effects have a significant negative impact on patients' quality of life.

As a result, the low therapeutic indices of these widely available therapy options have prompted a search for effective drug delivery systems that might optimize therapeutic efficacy while minimizing adverse effects. Targeting drugs with specially designed drug delivery systems is a profitable strategy to improve therapeutic efficacy and reduce the risk of systemic toxicity in anticancer therapy. As a result, developing precisely targeted pharmaceutical delivery systems is critical both therapeutically and for curing cancer before it kills the patient.

Cellular barriers

Concerns about long-term chemotherapy treatment have been raised by the development of multidrug resistance in tumor cells brought on by the expression of drug-efflux proteins on the cell surface .

Multi-drug resistance (MDR) issues can be resolved by delivering toxic medications into tumor cells in drug delivery systems. Drug resistance has been explained by a number of different mechanisms. In the majority of resistant cells, the intracellular accumulation of anticancer drugs is known to be decreased by the membrane-bound p-glycoprotein (PGP)-mediated efflux mechanism.

Additionally, several anticancer medications are ejected from vesicles after being trapped there. blocking some anticancer drugs (such as doxorubicin, CISPLATIN, and others) from localizing or delivering themselves effectively into the nucleus .

The membrane-associated multi-drug resistance proteins (MRPs) lessen the intracellular accumulation of certain other anticancer drugs, such as doxorubicin, by acting as their substrates .[3]

Drug resistance in cancer treatment is being addressed by a number of drug delivery strategies, including polymer-drug conjugates , liposome, NANO and micro particles , and polymeric MICELLAR systems .

Although the aforementioned techniques do not target cells, they may enhance the intracellular delivery of chemotherapeutic drugs when compared to medication in solution. to the nucleus directly.

With the aforementioned delivery methods, drug transport to the nucleus mostly relies on the passive diffusion of free drug from the cytoplasm to the nucleus, which may not be particularly effective.

This is due to the fact that P-GP has been demonstrated to express on intracellular organelles such the nuclear membrane envelope and the Golgi apparatus in addition to the plasma membrane. While another study showed the efflux of doxorubicin from the nucleus, lowering the amount of drug available in the nucleus for DN, et al.

Demonstrated the presence of P-GP on the nuclear membrane of multidrug resistant variations (MCF-7/ADR). Intercalation.

Thus, resistant cells establish an additional defense mechanism against anti drugs in the form of P-GP on the nuclear membrane envelope. Therefore, until there is increased drug localization in the nucleus, drug resistance may not be solved by merely providing the medication into the CYTOPLASMIC compartment.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

Furthermore, after intracellular internalization, some of the currently employed drug delivery systems may still be confined in Endo vesicles, which could limit their effectiveness .

Targeting Drugs for Cancer Treatment

There is an excess of molecular information as a result of the quick development of innovative methods in the field of molecular biology and the growing understanding of the molecular PATHOPHYSIOLOGY of diseases.

In fact, these advancements have happened so quickly that many molecular targets for therapeutic action have been discovered at a rate that is significantly faster than our current capacity to apply this molecular knowledge. [4]

Many efforts are currently underway to find and create medications that specifically block different signal transduction pathways found only in cancer cells.

This will allow for the customization of treatments based on the distinct set of molecular targets generated by the patient's tumor.

Drugs can be administered alone, in a drug delivery system that targets the cancer cell surface or certain organs where the tumor is located.

The existence of particular targets, LIGANDS for these targets, and methods of delivering the medication to the target via various delivery vehicles conjugated to the LIGANDS are the main elements of such targeted drug delivery.

Drug Delivery in Cancer Therapy

Exhibit a dynamic and diverse biology that is always evolving, posing new difficulties for medication administration .

Developing efficiently tailored medication delivery alternatives requires a deep understanding of the biology of tumor cells, their microenvironment, and their development patterns.

Drug targeting can be accomplished by actively targeting drug carriers using certain target-specific or by utilizing the unique PATHO physiological characteristics of a tumor tissue (Fig. 1).



Figure 1: Schematic representing different drug targeting approaches[5]

Passive Targeting

In order to enable the selective accumulation of medications at the tumor site,

Passive targeting strategies take advantage of the anatomical and function distinctions between the normal and tumor vasculature .



Figure :- Mechanism and advantages of passive targeting.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

EPR Effect :-

Compared to the vasculature seen in normal tissues, tumor vasculature is typically bigger, more permeable, and more diverse in distribution.

The vascular endothelium in tumor micro vessels is irregular and leaky, in contrast to the taut endothelium of healthy blood vessels.

Depending on the tumor's anatomic location, the size of the gaps between endothelial cells has been found to vary between 100 and 780 nm .

Additionally, the increased concentrations of growth hormones such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (BFGF) changes[6] tumor vasculature causing VASODILATION and improves medication delivery to malignancies.

This, in conjunction with solid tumors' reduced lymphatic outflow, enables the enhanced permeability and retention (EPR) effect, which is the term used to describe the increased accumulation and retention of high molecular weight medications in solid tumors .

The EPR effect has mostly been applied to passively target pharmaceuticals larger than 40 KDA and low molecular weight medications delivered to solid tumors using drug-carriers such as liposome, polymeric drug conjugates, polymeric NANOPARTICLES systems .

To profit from PATHO physiological opportunity, the targeted drug or drug-carriers should be therapeutically active for an extended period of time while in circulation .

The size of tumors, the level of tumor vascular, and angiogenesis are other factors that affect EPR.

Therefore, when employing the EPR effect to target drugs, the disease stage is crucial. There are currently two liposomal formulations on the market that use the EPR effect to deliver medications to tumors.

The doxorubicin-based DOXIL (Pharmaceuticals) and TM liposome (Inc.) are stabilized liposomal formulations with prolonged circulation durations that effectively accumulate in the tumor cells.

By lowering drug levels in the plasma, this passive targeting of anti-cancer medicines lessens the likelihood of these medications' common cardiac side effects

In order to investigate the prospect of passively targeting tumor tissues utilizing the EPR effect, low molecular weight medicines have also been attached to polymers.

A degradable peptide linker is used to bind therapeutic medicines to polymers; the active drug is released only after the linker breaks down inside the tumor cell.

These polymer-drug conjugates have been made using a range of block co-polymers, insulin, polysaccharide B, poly glutamate, and acid .

Maeda developed SMANCS, which is a conjugate of polystyrene- co- acid half-n-butyl (SMA) with neo Primary is treated with (NCS), a strong toxic agent Using such technologies has typically resulted in an early tumor regression followed by tumor remission from the remaining cells in the tumor's non-accessible parts.[7]

This happens because medication extraVASATION and penetration are restricted to the tumor's periphery.

The center of the tumor has a high interstitial fluid pressure, while the surrounding tissues and the periphery have comparatively low interstitial fluid pressures. Consequently, there is a sub substantial permeation of macromolecules in the peripheral regions of a tumor mass, in contrast to relatively less drug diffusion into the center of solid tumors.

These macromolecules must resist the interstitial fluid's outward flow, which can transport these medications to normal tissues by convection, in order to penetrate into the tumor's more necrotic interior areas .

Therefore, the EPR effect-using devices must be tuned for deep tumor penetration, or the tumor blood flow can be increased by co-administering various supplemental physiological modulators.

VEGF, BFGF, converting enzyme inhibitors like can variably increase the tumor blood flow and Consequently, medicines .

Localized Delivery:

It focuses drug levels at the site of action while delivering the medication directly to a localized tumor location, eliminating the medicine's systemic side effects.

But not all tumor types—like lung cancer—can benefit from this strategy.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

Nonetheless, such a strategy may work well for treating prostate cancer.
The combination of digital rectal examination, blood PSA (prostate specific antigen) level testing, and trans rectal ultrasound has significantly improved disease detection and staging during the last ten years
In North America, localized illness is found in about 90% of men with prostate cancer diagnoses.[7]
Consequently, an early intervention that uses less local treatment to address the disease showed full tumor regression in a prostate cancer model in subcutaneous mice .
If-conjugated NANO particles were found to be more effective than drug in solution or un conjugated NANO particles because of their higher cellular absorption and longer intracellular retention of the encapsulated medication .

Physical Targeting
This novel targeting technique targets the release of a medicine at a particular location within the body by using an external stimulus.

Ultrasound
By targeting the tumor tissue with ultrasonic waves, anti-cancer drugs can be released from polymeric micelles, facilitating the encapsulated drug's efficient intracellular uptake.
Furthermore, polymeric micelles have the ability to make multidrug-resistant (MDR) cells more sensitive to the effects of medications .
Although the exact targeting mechanism is still unknown, potential explanations include ultrasound-induced micelle extra into tumor tissue and a medication release that is initiated specifically at the ultrasound-irradiated tumor site .
The delivery of medications to drug-sensitive and MDR ovarian A2780 cancer cells has been investigated in vitro using this targeting approach.
Ultrasound can either encourage micelle breakdown or cause drug diffusion out of the micelles.
This technique's non-invasiveness, deep penetration into the body.

Magnetic Field
Using an external focused magnetic field, a therapeutic agent bound or encapsulated in a magnetic drug carrier is injected intravenously as part of the magnetic targeting strategy.[8]
This allows the therapeutic agent to be guided and preferentially targeted in the tumor tissue. Materials like magnetite, iron, nickel, cobalt, and so forth are frequently used as magnetically responsive medicinal carriers. These drug delivery systems include colloidal iron oxide solution (magnetic FERROfluids), magnetic liposome, microspheres, and NANO sphere .
Using appropriately positioned external magnets, magnetic FERROfluid (particle size 100 nm) coated with a unique carbohydrate that can reversibly bind pharmaceuticals was investigated for targeting tumor tissues .
Their purpose was to DESORB the medicine that was being transported. caused by specific physiological factors (PH).
In the first-ever Phase 1 clinical trials, patients with advanced sarcomas were tried to get magnetic targeting of the medicine EPIRUBICIN using the aforementioned targeting method .
Because of their low magnetic susceptibility, over 50% of the carriers ended up in the liver, despite the fact that this novel medication targeting strategy was proved to be safe and well tolerated in clinical settings.
As a result, the studies came to the conclusion that the targeting system requires enhancements in order to become more efficient and unaffected by issues pertaining to patients or diseases. Preclinical research on magnetic drug carriers is ongoing for a number of chemotherapy drugs, including PACLITAXEL, ETOPOSIDE, and .
Other concerns such as drug-carrying ability, water dispersion stability, and tissue biocompatibility should be addressed by the employment of magnetic carriers. Recently, we created a brand-new water-dispersible oleic acid.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024



Figure 2: Schematic representing water-dispersible oleic acid-Pluronic®-[9]

Drug Delivery in Cancer Therapy

High concentrations of water-insoluble anticancer drugs, such as PACLITAXEL, can be effectively loaded into a formulation of PLURONIC coated iron-oxide magnetic NANO particles (Fig. 2).

In vitro, this NANO particle formulation maintained the integrated drug's release for more than two weeks. Crucially, the magnetic characteristics of the core iron-oxide NANO particles were unaffected by the formulation parameters. tumor cells, without adversely affecting the surrounding High concentrations of water-insoluble anticancer drugs, such as PACLITAXEL, can be effectively loaded into a formulation of PLURONIC coated iron-oxide magnetic particles (Fig. 2).

In vitro, this particle formulation maintained the integrated drug's release for more than two weeks.

Crucially, the magnetic characteristics of the core iron-oxide particles were unaffected by the formulation parameters.

Without negatively impacting the surrounding environment, radioisotopes encapsulated in such magnetic drug carriers can be employed to deliver a focused high dose of radiation to the tumor cells.

The full magnetic carrier is transported to the desired irradiation area and kept nearby.

Targeting medications to the tumor location is a promising strategy, and cooperation between physicists and biologists would be necessary to advance the system.

A strong targeting magnetic force that can resist the force caused by the arteries' and blood capillaries' linear blood flow rates is necessary for an efficient targeting via systemic injection . In order to externally direct these magnetic drug carriers to the tumor location, efforts are focused on creating targeted carriers with a high magnetic moment or on creating magnets that can produce stronger magnetic field gradients[10].

Active Targeting

In order to provide more precise medication delivery, active targeting entails changing specific LIGAND , antibodies, or other molecules on the surface of NANO particles to recognize and bind to particular cells or tissues at the targeted region.

For example, the use of antibody-adorned NANO particles can recognize and bind to particular antigens on the outside of tumor cells, allowing for more accurate medication administration.

The four primary categories of active targeting are small-molecule-based targeting, APTAMER -based targeting, peptide-based targeting, and antibody-based targeting (refer to Figure 5).

The EPR effect is followed by the active targeting of NANO particles in vivo, which then uses surface changes to bypass the route and reach the targeted tumor site.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024



Figure:- Mechanism of active targeting and types of modifying LIGAND [11]

Tumor Vascular Endothelium

Using widely accessible targets and genetically stable endothelial cells that do not develop resistance to therapeutic drugs, targeting tumors via their vascular endothelium is a promising approach.

The anatomy and expression of functional receptors on the cell surface of the vascular endothelium in solid tumors are different from those in normal tissues.

Every solid tumor that has vasculature larger than 1-2 mm in diameter develops new blood vessels to meet the rapidly growing tumor cells' increasing needs for oxygen and nutrients.

Angiogenesis is the term for this process, which is characterized by the activation of preexisting endothelial cells and increased expression and cell adhesion factors. Because the vascular endothelium is extremely accessible to all circulating systems, it offers a variety of targets for cancer therapy, including endothelial cells and certain STROMAL components that can be exploited to target medications or drug-carriers .

The most popular target for tumor imaging and treatment is ENDOGLIN (CD105), the receptor for tumor growth factor (TGF-) .

Vascular endothelial growth factor (VEGF) is one of several growth factors that sustain the proliferation of tumor neo vasculature.

Anti-VEGF antibodies were tried to stop the growth of human tumor , but these MABS were unable to completely eradicate the tumors, and once treatment stopped, the tumors started to grow again .

In order to regulate tumor growth, anti-VEGF antibodies are currently being investigated in conjunction with chemotherapeutic drugs .

The targets found in the matrix are additional possible targets in the vascular endothelium. These include the angiogenesis-related targets: endothelial growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), matrix metal (MMPs), and their receptors (tie1 and tie2), and their receptors .

A particular endothelial cell adhesion protein called vascular endothelial (VE-cad) is essential for angiogenesis and vascular integrity during tumor progression. MABS against VE-cad inhibited the growth and spread of the tumor.

To organs in the distance . Since , particularly "v #5 " are only expressed during angiogenesis and are absent from healthy, mature blood vessels , they provide for thehighly intriguing molecular targets (Fig. 3).[12]

It has been discovered that MABS and, in particular peptides rich in ARG GLY-Asp (RGD), bind to and can therefore target the tumor endothelium .

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024



Figure 3: Treatment of mice bearing large (5 cm3) MDA-MB-435 breast carcinomas (four animals per group) were randomized to receive a single dose of free doxorubicin or doxorubicin-RGD-4C conjugate at 200 g of doxorubicin-equivalent per mouse. A Kaplan-Meier survival curve is shown. [Figure reproduced with permission from Ref.]

Tumor Cells

As a result of their altered nature, cancer cells over express numerous recognized proteins and express some novel ones as well.

These proteins can function as important biomarkers for the course of the illness as well as surrogate markers that give an indirect indication of how well a patient is responding to medication therapy .

The term "tumor associated antigens" (TAA) refers to certain proteins or biomarkers that are either substantially over expressed on cancer cells or preferentially expressed only in or on them

LIGANDS or antibodies, particular Drugs can be targeted to tumor cells using these TAAs.

Additionally, many cancer cells over express a range of cell surface receptors for peptides, hormones, and vital minerals like iron and folic acid, which makes it possible to target tumor cells with medications.

Melanoma antigen E (MAGE)-1, which was discovered to be over expressed on tumor surfaces, was the first TAA to be discovered and cloned .

The hunt for new TAA has been sparked by developments in the domains of proteomics and bioinformatics .

On the surface of tumor cells, an ideal tumor-associated antigen should be expressed preferentially.

An antigen that is essential to the cancer cells would be very significant since antibodies would be produced against it.

Tumor cells undergo apoptosis when exposed to HERCEPTIN® (Genentech), an antibody that blocks Her-2, a tyrosine present in breast cancer cells .

Although these tumor-specific functional targets are highly desired, so far, very few have been found.

Conjugating therapeutic moieties to antibodies or LIGANDS against the nonfunctional TAA and using their specificity to deliver toxins to the tumor cells in a highly specific way is another way to target tumor cells.

And the transfer receptor are a few prominent types of tumor-specific targets that have been employed in immunotherapy.

FOLATE Receptor

More than 90% of individuals with ovarian carcinoma and many other cancer forms (such as CHORIO carcinomas, uterine sarcomas, and OSTEO carcinomas) have over expressed FOLATE receptors (FR), a highly specific tumor marker. Due to its low levels in the kidney and lungs and its absence in most normal tissues save the placenta and choroid plexus, it has drawn a lot of attention for drug targeting purposes .

Furthermore, the potential to target the FOLATE receptor with an antibody or small molecule LIGAND(folic acid) enhances the chances of delivering medications or drug-carriers to tumor cells through FR.[13]

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

LDL Receptor

Low density lipoprotein (LDL) receptors are ENDOCYTIC receptors that use receptor-mediated ENDOCYTOSIS to deliver cholesterol-rich lipoproteins (LDL) into cells .

Drug-loaded liposome can be more readily absorbed by cancer cells through LDL receptor-mediated ENDOCYTOSIS when liposome are engineered to resemble LDL and interact with the LDL receptors on the cancer cells .

Hormone Receptors

Many hormone-dependent cancers have hormone receptors on their cell surface, which are another type of tumor cell-specific targets .

There have been reports hormone releasing hormone (GNRH/LHRH) receptors in cell lines of numerous hormone-dependent tumors, including ovarian, breast, prostate, and endometrial cancers, as well as in certain solid tumors.

Antibodies against this receptor or certain LIGAND, such as LHRH or its synthetic peptide counterpart, can be used to target tumor cells with anti-tumor therapy .

The area of new tumor-associated targets has exploded as a result of the identification and confirmation of tumor-associated antigens and targets.

In the meanwhile, it's critical to compre hend the existence of these targets in order to successfully use them for medication targeting.

In view of the molecular and cellular pathogenesis of tumors.

The majority of tumor tissues are heterogeneous, and this heterogeneity varies from patient to patient in addition to depending on the disease's aggressiveness and stage.[14]

As a result, not every patient will have the molecules that are over expressed in a certain type of cancer.

This further calls for the identification of patient populations that over express particular proteins on the tumor cells (using gene microarray analysis) .

It's possible that these cell surface molecules' expression varies unevenly throughout the tumor bulk.

This could be caused in part by genetic instability brought on by hypoxia in the tumor's inner areas or by variations in the patterns of This could be caused in part by variations in the patterns of posttranslational modifications of the protein within the tumor mass or by genetic instability brought on by hypoxia in the internal parts of the tumor.

In some areas of the tumor, decreased or absent antibody reactivity may result from further variations in the level of GLYCO of a tumor-specific antigen.

If the toxic drug is stable and administered in sufficient quantities to give the antigen-negative cells a "bystander effect" (because the antigen-positive cells release the drug into the inter), heterogeneity in the expression of surface proteins might not be a significant limiting factor.

For a tightly binding antibody, extremely high antigen expression is also troublesome since it decreases tumor the medication or antibody-drug combination.

Additionally, the majority of cancer patients receive multi-drug therapy, thus it's critical to confirm that the target's expression on the cancer cells persists long after these therapies are finished.

Many cancer cells release surface antigen molecules into the bloodstream when they begin to spread to other areas in advanced stages of the disease.

Because these blood-stream antigens are easier for a targeted drug delivery system to reach, they compete with the bound antigen on tumor cells, reducing the therapeutic efficacy.

It's possible that these cell surface molecules' expression varies unevenly throughout the tumor bulk.[15]

This could be caused in part by genetic instability brought on by hypoxia in the tumor's inner areas or by variations in the patterns of This could be caused in part by variations in the patterns of posttranslational modifications of the protein within the tumor mass or by genetic instability brought on by hypoxia in the internal parts of the tumor.

In some areas of the tumor, decreased or absent antibody reactivity may result from further variations in the level of GLYCO of a tumor-specific antigen.

If the toxic drug is stable and administered in sufficient quantities to give the antigen-negative cells a "bystander effect" (because the antigen-positive cells release the drug into the inter), heterogeneity in the expression of surface proteins might not be a significant limiting factor.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

For a tightly binding antibody, extremely high antigen expression is also troublesome since it decreases tumor the medication or antibody-drug combination.

Additionally, the majority of cancer patients receive multi-drug therapy, thus it's critical to confirm that the target's expression on the cancer cells persists long after these therapies are finished.

Many cancer cells release surface antigen molecules into the bloodstream when they begin to spread to other areas in advanced stages of the disease.

Because these blood-stream antigens are easier for a targeted drug delivery system to reach, they compete with the bound antigen on tumor cells, reducing the therapeutic efficacy.[16]



FIGURE :- Hormone receptor in breast cancer

Drug Delivery in Cancer Therapy

LIGANDS :-

A substance that has a high affinity for binding to cell surface proteins can be used as a targeting moiety to direct medications or drug carriers to the tumor location.

The perfect targeting agent would be one that can be manufactured in large enough numbers, has a high affinity and specificity for binding to cell surface receptors, and is amenable to chemical modification for conjugation .

Antibodies against certain cell surface targets have been widely employed for medication targeting since the advent of the idea of "magic bullets." introduction of HYBRIDOMA methods for mass production of monoclonal antibodies (MABS), and Antibodies as targeting agents have also garnered a lot of interest due to methods for creating smaller antibody fragments, or antibodies.

Furthermore, in order to prevent an immunological reaction against MURINE antibodies, new techniques have been developed to create humanized monoclonal antibodies rather than mouse monoclonal antibodies .

These methods involve grafting mouse antigen binding domains onto human acceptor antibody frameworks (humanization of antibodies), removing T-cell EPITOPOSIDE (de-immunization), and fusing mouse variable regions to human constant regions (antibodies).

Hematologic cancers and lymphomas have been effectively treated using MABS[17]

However, because these big molecules have a hard time penetrating the tumor mass, antibodies' effectiveness as targeted agents is limited for solid tumors.

Therefore, it was hypothesized that employing antibody fragments as small as feasible to boost the targeting efficiency of antibodies would allow these smaller molecules to more equally infiltrate tumors .

Mono fragments, single chain Fv fragments (SCFV), and antibodies are examples of these novel antibody forms. They leave the bloodstream somewhat quickly, in contrast to smaller fragments that have consistent penetrability.

Additionally, scientists hypothesized that substances smaller than antibodies (such as hormones, peptides, cytokines, and specific In conclusion, the choice of a specific targeting agent is a crucial factor that may influence the medication targeting strategy's eventual success.

It is crucial to remember that not all tumor-cell related surface proteins are receptors or binding proteins with particular LIGAND; as a result, antibodies can be used to target them.

The usage of LIGAND is further restricted by their promiscuity to bind to several receptors with very comparable affinities, whereas the specificity of antibodies can be carefully tailored to a specific sequence or some characteristic fold in the tertiary structure of the cell surface target.

The targeted LIGAND non-specific binding The therapeutic availability of the targeted system at the targeted tumor site would be decreased if the LIGAND were to serve as a sink at non-target sites.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

When choosing a targeting agent, the stability of the agent in the bloodstream is another important consideration, as is the targeting agent's in vivo half-lives .

Short half-lives in the serum caused by proteolysis, de , or binding to non-target sites restrict the targeted drug delivery system's ability to reach the target (tumor tissue).

There should be a wealth of information accessible regarding the structure and associated activity of the targeting agent since this would aid in determining the chemistry for conjugating it to a drug or drug-carrier by altering the structure of the targeting antibody or when certain small molecule LIGAND are not available, and when the surface target .

Drug Carrier Systems

Naked Antibodies :-

Antibodies produced against the antigens linked to tumors, which are essential for cell proliferation, can act as a therapeutic alternative for tumor treatment on their own.[18]

HERCEPTION® (TRASTUMB, Genentech), an antibody against Her-2, a tyrosine kinas present in breast cancer cells, is one example.

Clinically helpful against metastatic breast tumors that over express Her-2, HERCEPTION® is an un conjugated humanized monoclonal antibody against Her-2 that causes tumor cells to undergo apoptosis.

Another monoclonal antibody that targets vascular endothelial growth factor (VEGF), which is implicated in tumor angiogenesis, is ® .

When used in conjunction with conventional treatment, increases the overall survival rate of patients with colorectal cancer .

IMMUTOXINS :

Whole monoclonal antibodies to bacterial or plant toxins, such as diphtheria toxin and pseudomonas EXOTOXIN, conjugate to form IMMUNOTOXINS.

By altering or removing the toxin's capacity to attach to its own receptor, non-specific toxicity caused by these natural toxins can be eradicated .

At greater dosages, these targeted toxins nevertheless have a significant chance of being non-specifically harmful to healthy cells

CHIMERIC PROTEINS

These novel and intriguing tailored chemicals identify and eliminate tumor cells that over express particular IC receptors.

Chemical conjugates of certain minor cytokines, hormones, or growth factor-based LIGANDS with natural poisons, such diphtheria toxin and pseudomonas EXO toxin (PE), are known as CHIMERIC proteins .

In a model of colon cancer in naked mice, CHIMERIC proteins made with a GNRH analog linked to PE prevented the development of tumors by 80% .

PE destroys the tumor cells by preventing protein synthesis, whereas GNRH serves as the targeting moiety for ADENO carcinoma cells (Fig. 4).[19]

The use of such CHIMERIC proteins is restricted by their non-specific toxicity to HEPOTASITES and the production of the human immune response to bacterial toxins.

Human pro-apoptotic proteins with low immunogenicity have been delivered as a basis for a new generation of CHIMERIC proteins .

The idea of delivering apoptotic proteins, in the form of In a colon cancer mouse model, the idea of apoptotic protein delivery—targeting CHIMERIC proteins—was demonstrated to be effective in preventing tumor growth.

Because it uses proteins of human origin, the new system has a lower risk of immunogenicity when administered to humans than the previous ones.

Additionally, because normal cells lack surface receptors for the hazardous proteins, there is a decreased likelihood of non-specific toxicity because the apoptosis-inducing proteins have internal targets.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024



Figure 4: The effect of purified GnRH-PE66 on XENO graft formation in nude mice. Caco-2 colon carcinoma cells (2.2 106) were injected sub into nude mice.[20]

NANO SYSTEMS /Drug Carriers

Using LIGANDS or antibodies against tumor-associated cell surface receptors anti-cancer medications can be linked to colloidal drug carrier systems including polymeric micelles, NANO particles, and liposome.

These systems can then be actively targeted to certain tumor cells.

Targeted drug administration can increase selectivity and circumvent cellular-based mechanisms of multi-drug resistance.

of medication administration to cancerous cells .

Anticancer drugs included in NANO particles avoid the emergence of multi-drug resistance since they are not detectable by the cellular efflux systems.

When manufactured in the right sizes and possessing long-circulating qualities in the bloodstream, such NANO-sized drug carriers can passively accumulate in the tumor tissue through the EPR effect. Additionally, the NANO particles' surfaces can be altered to enable certain biochemical interactions with the proteins and receptors expressed on tumor cells.we have shown that PACLITAXEL-loaded NANO particles are more effective when conjugated with transfer.

transfer antibodies have been used to target medications to tumor cells since are over expressed in tumor cells by 2–10 times compared to normal cells.

In a mouse model of prostate cancer, a single intra TUMORAL injection of transfer-conjugated PACLITAXEL NANO particles resulted in a full regression and a noticeably greater survival rate compared to the un conjugated NANO particles or medication dissolved in EL (Fig. 5).

The increased effectiveness of transfer conjugated NANO particles was caused by increased cellular absorption of the medication administered by the NANO particles.[21]



Figure 5: Antitumor activity of paclitaxel (Tx)-loaded nanoparticles (NPs) conjugated to transferrin (Tf) in prostate tumor model. PC3 cells (2 106 cells) were implanted s.c. in athymic nude mice.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

Bio conjugation Chemistry/Linkers

Through well planned chemical conjugation processes, the CYTOTOXIC medication or a drug carrier can be connected to the targeted agent.

A spacer or linker may be used, or the targeted moiety may be directly attached to the medication or drug-carrier.

The chemical is selected so that it doesn't negatively impact the target specificity or activity.

Linkers for Bio conjugation.[22]

Drug Delivery in Cancer Therapy



Figure 5: Possible mechanism of intracellular ara C delivery by FR-targeted cationic lipid-based pH-sensitive liposome. At first, the folate- liposome are taken into the cell via binding to the FRs on the plasma membrane and FR-mediated

ENDOCYTOSIS

Agent and the medication, in that order . By lowering STERIC hindrance and increasing LIGAND mobility, the use of a linker between the medicinal substance and the targeted moiety improves the effectiveness of interacting with biological receptors.

When the medication enters the cell by ENDOCYTOSIS, the linkers can be engineered to provide more control over the release of the drug from its carrier.[23]

This facilitates the integration of drug-carrier targeting and efficient intracellular internalization (Fig. 6) . Chemical processes employing particular functional groups or chemical moieties in the drug and targeting agent are used to conjugate a targeting agent to a drug or its carrier; these reactions are not necessary to preserve the compound's intended bio.

Challenges

Numerous obstacles arise when medications are targeted to solid tumors that are localized in a certain tissue; however, these problems become increasingly complex when the tumor cells begin to spread to adjacent tissues.

To find suitable future targets that can be used to target medications to the tumor cells, it is essential to comprehend the molecular factors influencing metastasis.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

The location of the cancer cells' metastases would also determine the molecular targets. A common side effect of solid tumors, such as breast and prostate cancer, is skeletal metastasis, which is typically incurable .

The majority of the therapy options currently available are palliative in nature and only temporarily effective .

Despite the fact that numerous novel therapeutic targets have been suggested, the absence of suitable drug delivery mechanisms has hindered any improvements in patient-accessible healthcare choices.

Therefore, a drug delivery strategy that can get beyond physiological and anatomical obstacles and deliver medications precisely to the bone metastasis location is crucial .

This would enable achieving therapeutic drug concentrations at the illness site in addition to preventing the drugs' non-specific systemic side effects.

Concluding Remarks

When drugs are delivered to tumors specifically, they can kill cancer cells more selectively, reduce the peripheral toxicity and may allow for an increase in dosage.

There is optimism that a viable targeted drug delivery mode for cancer therapy will be developed as a result of developments in the discovery of tumor-specific targets and the creation of various drug delivery strategies for tumor targeting.[24]

More pragmatic objectives that attempt to enhance patients' quality of life are almost attained, even though the ultimate goal is to eradicate cancer from the patient.

In the coming years, special attention will be paid to the creation of systems that can effectively internalize into cancer cells in addition to identifying precise targets on the cells.

Some of these issues may be resolved by combining different targeting strategies.

Additionally, by employing particular molecular addresses on the vascular endothelium, focusing on Some of the new ideas that have great potential for drug targeting in cancer treatment include the use of magnetic fields and ultra SONOGRAPHY.

Better knowledge of the illness, the discovery of tumor-specific indicators, and the concurrent creation of novel medications that are more effective and less harmful are all necessary for all of these.

Drug discovery projects should be conducted concurrently with the development of new drug delivery systems in order for new medications to reach the clinic.

This will prevent the drugs from experiencing adverse pharmacokinetics and being rejected during the development process.

The likelihood that novel anticancer medications will reach patients can be increased by using targeting tactics that use nanotechnology and bio conjugation chemistry, which can change a drug's bio distribution to prevent toxicity and boost its efficacy.[24]

II. CONCLUSION

Targeted drug delivery systems (TDDS) represent a promising advancement in cancer therapy by enhancing the efficacy of treatments while minimizing side effects. Traditional cancer therapies, such as chemotherapy, often affect both cancerous and healthy cells, leading to toxicities and reduced patient quality of life. In contrast, TDDS aims to deliver drugs specifically to cancer cells, improving the precision of treatment.

Through the use of nano particles, monoclonal antibodies, or other carriers, TDDS allows for the targeted release of drugs at the tumor site, increasing the concentration of the therapeutic agent in cancerous tissue while sparing normal tissues. This targeted approach not only improves the therapeutic index of drugs but also opens the possibility of overcoming challenges such as drug resistance and tumor heterogeneity.

Moreover, TDDS platforms, including liposome, and magnetic nano particles, are being tailored for specific cancer types, enhancing their ability to cross biological barriers like the blood-brain barrier in cases of brain tumors. These systems can also incorporate imaging agents for diagnostic purposes, leading to better monitoring of treatment response and tumor progression.

Despite the significant progress, challenges remain in the development of TDDS, such as optimizing the design, ensuring stability, managing the complexity of tumor environments, and overcoming regulatory hurdles. However,

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

ongoing research continues to refine these systems, and clinical trials have demonstrated the promising potential of TDDS in cancer therapy.

In conclusion, targeted drug delivery systems hold immense promise for improving cancer treatment outcomes by offering a more selective and personalized approach. As these systems evolve, they are expected to revolutionize cancer therapy, reduce side effects, and provide new hope for patients with various types of cancer.[25]

REFERENCES

[1]. Beardsley, T. A War not Won. Sci Am 270, 130-138 (1994).

[2]. Delivery of Molecular and Cellular Medicine to Solid Tumors, R. K. Jain. (2001) Adv Drug Deliv Rev 46, 149-168.

[3]. Wientjes, M. G., Jang, S. H., Lu, D., and Au, J. L. Drug Transport and Delivery to Solid Tumors. (2003) Pharm Res 20, 1337-1350.

[4]. Chari, R. V. Tumor-activated Prodrug Therapy: Targeted Chemotherapeutic Delivery. (1998) Adv Drug Deliv Rev 31, 89-104.

[5]. Haveman, J., Peters, G. J., Franken, N. A., Loves, W. J., van Bree, C., and Castro Kreder, N. Gemcitabine-resistant human tumor cell lines' sensitivity to ionizing radiation and chemotherapy agents. 54, 237-244 (2002); Int J Radiat Oncol Biol Phys.

[6]. Krishna, R. and Mayer, L. D. Cancer and Multidrug Resistance (MDR). mechanisms, Reversal Using MDR Modulators and the Function of MDR Modulators' Effect on Anticancer Drug Pharmacokinetics. (2000) Eur J Pharm Sci 11, 265-283.

[7]. Links, M., and Brown, R. Molecular Mechanisms of Resistance to Anti-Cancer Drugs: Clinical Significance. 1999, 1-21; Expert Rev Mol Med (1999).

[8]. Robert, J., Bennis, S., Chapey, C., and Couvreur, P. Polyisohexylcyanoacrylate nanosphere-encapsulated doxorubicin exhibits enhanced cytotoxicity against multidrug-resistant tumor cells in culture. 89-93 in Eur J Cancer 30A (1994).

[9]. Kristel, P. M., van de Vijver, M. J., and Faneyte, I. F. Assessing the Expression of MDR1/P-glycoprotein in Breast Cancer. 114–122 in Int J Cancer 93 (2001).

[10]. Marra, M., Colone, M., Cianfriglia, M., Arancia, G., Crateri, P., Toccacieli, L., Calcabrini, A., Meschini, S., Stringaro, A., and Molinari, A. Drug Transporter Pglycoprotein Subcellular Detection and Localization in Cultured Tumor Cells. In 2002, Curr Protein Pept Sci 3, 653–670

[11]. Appel, M., Ferte, J., Bernard, S., Puisieux, F., Couvreur, P., de Verdiere, A. C., Dubernet, C., Nemati, F., Soma, E., and Appel, M. Using Polyalkylcyanoacrylate Nanoparticles to Reverse Multidrug Resistance: Toward a Mechanism of Action. (1997) Br J Cancer 76, 198-205.

[12]. Miyamoto, Y., Maeda, H., and Seymour, L. W. Anticancer Agent and Polymer Conjugates: Benefits of In Vivo Macromolecular Therapeutics. 1992; Bioconjug Chem 3, 351-362.

[13]. Doxorubicin in Sterically Stabilized Liposomes, Lasic, D. D. Nature (1996), 380, 561-562.

[14]. Kataoka, K., and Kakizawa, Y. Block Copolymer Micelles for Gene and Related Compound Delivery. 203–222 in Adv Drug Deliv Rev 54 (2002).

[15]. Block Copolymer Micelles for Drug Delivery: Design, Characterization, and Biological Significance by Kataoka, Harada, and Nagasaki, K. (2001) Adv Drug Deliv Rev 47, 113-131

[16]. Meschini, S., Calcabrini, A., Arancia, G., Cianfriglia, M., Stringaro, A., and Molinari, A. P-glycoprotein was found in the nuclear envelope of cells that are resistant to drugs. (2000) Histochem J 32, 599-606.

[17]. Liang, Y. J., Yang, X. P., Pan, Q. C., Zhang, Y. M., and Fu, L. W. Tetrandrine reversed the multidrug resistance of tumor cells both in vitro and in xenografts made from human breast adenocarcinoma MCF-7/adr cells. (2002) Eur J Cancer 38, 418-426.

[18]. Molinari, A., Meschini, S., Arancia, G., Cianfriglia, M., and Calcabrini, A. Intracellular P-glycoprotein in Multidrug Resistant Tumor Cells..59–68 in Ital J Anat Embryol 106 (2001).

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 1, December 2024

[19]. Qiu, B., Lalloo, A., Won, R., Stein, S., Minko, T., Paranjpe, P. V., and Minko, P. J. Using biotinylated poly(ethylene glycol) conjugates to increase the anticancer efficacy of camptothecin in human ovarian cancer cells that are sensitive and resistant to many drugs. 143–150 in Cancer Chemother Pharmacol 50 (2002).

[20]. Labhasetwar, V., and Sahoo, S. K. Sustained Intracellular Drug Retention Mediates the Increased Antiproliferative Activity of Transferrin-conjugated Paclitaxel-loaded Nanoparticles. Mol Pharm. (2005), in press.

[21]. In Determinants of Drug Delivery and Transport to Solid Tumors, Au, J. L., Jang, S. H., Zheng, J., Chen, C. T., Song, S., Hu, L., and Weientjes, M. G. 31–46 in J Control Release 74 (2001)

[22]. Jang, S. H., Wientjes, M. G., and Au, J. L. Clinical Aspects of Drug Delivery to Tumors. 81-95 in J Control Release 78 (2002).

[23]. Casarett, G., and Rubin, P. Tumor microcirculation. I. Necrosis, Function, and Anatomy. In 1966, Clin Radiol 17, 220-229.

[24]. Vascularization of Tumors: A Review, Shubik, P. In 1982, J Cancer Res Clin Oncol 103, 211-226.

[25]. Hobbs, S. K., Torchilin, V. P., Jain, R. K., Yuan, F., Roberts, W. G., Griffith, L., and Monsky, W. L. The function of tumor type and microenvironment in regulating transport pathways in tumor vessels. (1998) Proc Natl Acad Sci USA 95, 4607-4612.